Double Installation of EOS Systems in Australia

EOS Imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced the installation of the EOS imaging system in two prominent Australian medical facilities: the Royal Children's Hospital Melbourne (RCH), one of the largest pediatric hospitals in the country, and at Southern Radiology in Sydney, a leading private medical imaging center. The installation at the RCH highlights a significant milestone as the Company celebrates the 100^th installation of an EOS system.

RCH is one of the preeminent pediatric hospitals in Australia and the largest in the state of Victoria. EOS is part of its New Royal Children's Hospital Project, which was officially opened by Her Majesty Queen Elizabeth in late October 2011. The Project has received numerous international awards, including the "Best International Health Project” at the International Design and Health Academy Awards 2012. Southern Radiology is a leading specialist for medical imaging in Sydney area, operating nine practices with 13 Radiologists and 173 employees throughout the state of New South Wales.

The RCH installation marks the 100^th of an EOS equipment worldwide. The EOS system is operating today in 56 European and Middle-Eastern, 33 North American and 11 Asian and Pacific health centers in 17 countries. The system has also received clearance to market in more than 33 countries, allowing for a further growth of its geographic coverage and adoption.

Marie Meynadier, CEO of EOS imaging, said, "We are thrilled to reach this important milestone in our Company’s history, particularly with a double installation in two leading Australian facilities. Our 100^th installed unit is a strong testimony to the EOS system’s increasing adoption by medical facilities across the globe and the growing level of trust and credibility that has been established among physicians, researchers, academic hospitals and private practices.”

The EOS system provides full-body stereoradiographic images of patients in functional positions, in both 2D and 3D. With 50% to 85% less dose than Digital Radiology and 95% less dose than basic CT scans, EOS is fully in accordance with the ALARA (As Low As Reasonably Achievable) principle of radiation reduction.

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit http://www.eos-imaging.com/.

About EOS imaging:

EOS imaging designs, develops, and markets EOS® and associated solutions, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market in 33 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 106 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

EOS imaging is listed on Compartment C of Euronext Paris

ISIN: FR0011191766 – Ticker: EOSI

Next press release: revenue for the 3^rd quarter of 2014, on October 22, 2014 (after market).